NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NURO opened at $4.55 on Thursday. The business’s 50-day moving average is $4.44 and its two-hundred day moving average is $4.22. The company has a market capitalization of $9.37 million, a P/E ratio of -0.99 and a beta of 1.82. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. GTS Securities LLC purchased a new position in shares of NeuroMetrix during the 4th quarter valued at approximately $90,000. Deltec Asset Management LLC acquired a new stake in NeuroMetrix during the first quarter valued at $81,000. Finally, Renaissance Technologies LLC acquired a new stake in NeuroMetrix during the fourth quarter valued at $46,000. 19.40% of the stock is owned by institutional investors and hedge funds.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.